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Both mucosal-associated invariant and natural killer
T-cell deficiency in multiple myeloma can be 
countered by PD-1 inhibition 
Mucosal associated invariant T (MAIT) cells primarily
contribute to immune defense against infectious
pathogens and regulate pathogenesis of various inflam-
matory diseases.1 They are innate-like T lymphocytes
expressing an invariant TCR Vα7.2-Jα33 chain in humans
and displaying high expression levels of CD161 and IL-
18R. They are primarily localized in mucosal tissue and
respond to vitamin B2 metabolites in an MHC class 1b
(MR1)-dependent manner.1 Despite a different ontogeny,
MAIT cells share a close lineage relationship with invari-
ant natural killer T (iNKT) cells, another invariant T-cell
subset recognizing glycolipids and important for anti-
tumor immunity.1,2 Moreover, it has been suggested that
they share a common niche and could therefore be func-
tionally redundant.3 Recently, MAIT cells have been
implicated in cancer and were shown to support anti-
tumor immunity;4 however, their exact role has not been
well explored. Until now, most reports on involvement
of MAIT cells in cancer have been limited to mucosa-
associated cancers.5 Recently, however, Wallace et al.
reported MAIT cell deficiency in chronic lymphocyte
leukemia (CLL), suggesting a possible involvement of
MAIT cells in hematologic malignancies as well.4 Further
investigation of MAIT cell functionality in cancer
patients beyond mucosa-associated malignancies is,
therefore, warranted. In multiple myeloma (MM), invari-
ant T cells such as iNKT cells have been reported by us
and others to be deficient.6 This has not yet been investi-
gated for MAIT cells and whether they prove to be
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Figure 1. MAIT-cell numbers are decreased in
newly diagnosed multiple myeloma (NDMM)
patients compared to healthy controls and
correlate with decreased invariant natural
killer T-cell (iNKT) numbers. (A) Flow cytometry
data plots illustrating the MAIT-cell gating strat-
egy in the peripheral blood and bone marrow
(BM) of healthy controls (n=14) and NDMM
patients (n=14). (B) MAIT-cell percentages
within peripheral blood and BM T cells in
healthy controls and NDMM patients. (C)
Representative MAIT-cell subsets as deter-
mined by flow cytometry and (D) CD8+ and
CD4–CD8– MAIT-cell percentages within periph-
eral blood and BM T cells in healthy controls
and NDMM patients. (E) Spearman’s correla-
tion analysis between MAIT-cell levels and
NKT-cell levels in blood and BM of NDMM
patients. *P<0.01, **P<0.001.
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important in MM has not been established. Their similar-
ities with iNKT cells and their regulatory functions,
together with recent reports suggesting their possible
involvement in non-mucosa-associated malignancy,
make them a logical candidate for further studies.
Therefore, we examined the phenotype and functionality
of MAIT cells in MM. 
A total of 14 newly diagnosed MM (NDMM) patients
and 14 age-matched healthy controls were enrolled in
this study (patients' clinical characteristics are available in
Online Supplementary Table S1). The frequency of MAIT
cells (CD3+Vα7.2+CD161+) in total CD3+ lymphocytes
was determined by flow cytometry in peripheral blood
(PB) and bone marrow (BM) of NDMM patients and
healthy counterparts (Figure 1A). MAIT cell percentages
were significantly lower in NDMM patients compared to
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Figure 2. Impaired functionality of MAIT cells in newly diagnosed multiple myeloma (NDMM) patients compared to healthy controls. (A) Representative IFN-
γ, IL-17, and TNFα expression levels in the MAIT-cell population of healthy individuals (n=7) and NDMM patients (n=7), as determined by intracellular flow cytom-
etry after stimulation with PMA and ionomycin. (B) Percentages of IFN-γ, IL-17, IL-22 and TNFα levels produced by MAIT cells in response to PMA and ionomycin
are illustrated. (C) Flow cytometry data plots of CD69 and CD25 expression levels within the MAIT-cell population of healthy donors (n=7) and NDMM patients
(n=7) after three days of stimulation with or without α-GalCer. (D) Percentage CD69 and CD25 positive NKT and MAIT cells after three days of stimulation with
or without α-GalCer. DMSO: DMSO vehicle; α-GalCer: alpha-galactosyl ceramide. *P<0.05, **P<0.001.
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healthy individuals (Figure 1B). Reduced circulating
MAIT cell numbers have also been reported in autoim-
mune disorders [e.g. systemic lupus erythematosus (SLE),
rheumatoid arthritis and multiple sclerosis] and infectious
diseases (tuberculosis, HIV) along with malignancies
(chronic lymphocytic leukemia  and mucosa-associated
cancers).4,5,7-11 However, we are the first to show MAIT
cell disturbances in MM. MAIT cells can be subdivided
into CD4+, CD8+ and double negative subsets (Figure 1C).
In PB and BM, most of the MAIT cells carry either a CD8+
or a double negative phenotype. Analysis of MAIT cells
in NDMM patients by flow cytometry revealed signifi-
cantly lower percentages of the CD8+ MAIT cell subset
and the double negative fraction (Figure 1D), while the
CD4+ fraction remained unchanged (data not shown).
Therefore, reduced CD8+ and DN subset levels seem to
contribute to total MAIT-cell number reduction in MM.
Similar observations were published for SLE, HIV and
multiple sclerosis, but have not yet been reported in
other cancers.8,10,11 
In addition, similar decreases of iNKT-cell numbers in
MM could be observed (Online Supplementary Figure S1A
and B), in line with earlier reports.6 Since MAIT and iNKT
cells share a close lineage relationship, we subsequently
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Figure 3. Increased PD-1 levels on MAIT and
iNKT cells in newly diagnosed multiple myelo-
ma (NDMM) patients and restoration of MAIT-
cell activation by  invariant natural killer T-cell
(iNKT) stimulation and PD-1 blockade in vitro.
(A) Flow cytometry data plots illustrating PD-1
expression levels on MAIT and iNKT cells in
the peripheral blood and bone marrow (BM) of
healthy controls (n=14) and NDMM patients
(n=14). (B) Percentages of PD-1 positive NKT
and MAIT cells among peripheral blood and
BM in healthy controls (n=14) and NDMM
patients (n=14). (C) Percentage of CD69 and
CD25 positive cells within the MAIT-cell popu-
lation of healthy donors (n=7) and NDMM
patients (n=7) after three days of stimulation
with or without α-GalCer and anti-PD-1.
DMSO: DMSO vehicle; α-GalCer: alpha-galac-
tosyl ceramide; programmed death 1 check-
point molecule (PD-1). *P<0.05, **P<0.001.
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evaluated a potential relationship between them in
NDMM patients, by analyzing the association between
the MAIT-cell levels and iNKT-cell levels (Figure 1E).
Spearman’s correlation analyses revealed a significant
correlation between MAIT cell percentages and the total
iNKT-cell levels in NDMM patients, suggesting that
MAIT-cell deficiency is linked to iNKT-cell impairment.
Next, we evaluated the cytokine profile of MAIT cells
in order to determine their functionality in NDMM.
Peripheral blood mononuclear cells (PBMCs) from 7
NDMM patients and 7 healthy controls were stimulated
for 4 hours in the presence of PMA and ionomycin.
Subsequently, expression levels of IFN-γ, IL-17, IL-22 and
TNFα were examined by flow cytometry (Figure 2A).
Expression of IFN-γ, IL-17, IL-22 and TNFα was absent
on unstimulated MAIT cells of both patients and healthy
individuals (data not shown). However, when stimulated,
percentages of IFN-γ and TNFα positive MAIT cells were
found to be significantly reduced in PBMCs derived from
NDMM patients compared to healthy controls (Figure
2B). IL-17 and IL-22 MAIT cell expression levels were
unchanged between NDMM patients and healthy donors
(Figure 2B). As described in other studies, the majority of
MAIT cells (80-90%) produce TNFα and IFN-γ compared
to a minority (3% on average) of IL-17 and IL-22–produc-
ing MAIT cells.2 Together, these data suggest that MAIT
cells of NDMM patients have a disturbed Th1 function.
This could  either be due to reduced production of Th1
cytokines or to polarization of their cytokine profile.
In order to assess whether iNKT cells have the capacity
to activate MAIT cells, PBMCs from 7 NDMM patients
and 7 healthy controls were incubated for 72 hours in the
presence or not of α-GalCer, a strong glycolipid agonist
for iNKT cells. Subsequently, CD69 and CD25 expres-
sion was determined in the MAIT-cell population by flow
cytometry (Figure 2C). In healthy subjects, marked
increases of CD69+ and CD25+ MAIT cells could clearly
be observed after stimulation with α-GalCer in compari-
son with vehicle conditions (Figure 2D). In contrast, per-
centages of CD69+ and CD25+ MAIT cells were markedly
reduced upon iNKT stimulation in NDMM patients.
These findings suggest that a dysfunction of iNKT cells,
MAIT cells or a combination of both could be responsible
for a reduced activation of MAIT cells in NDMM
patients, as has also been observed in SLE.10 Altogether,
this further supports the intriguing concept that dysfunc-
tional iNKT-MAIT cell interactions can be involved in
pathological conditions. Although the underlying mecha-
nisms of crossregulation between iNKT and MAIT cells
are still not unknown, it can be anticipated that iNKT-
MAIT cell communication is partly cytokine mediated.
However, it should also be noted that iNKT-cell activa-
tion leads to bystander stimulation of a broad range of
downstream effector cells, including NK cells which
could potentially also contribute to MAIT cell activation.1
This will be the subject of future research.
PD-1 is a well-known target for immune checkpoint
inhibition in cancer, as tumor cells are able to evade the
immune system by PD-1 – PDL1/2 signaling. In conven-
tional T cells, PD-1 is absent on naïve T cells but up-reg-
ulated after T-cell activation. Recent reports highlighted
PD-1 and its ligand PD-L1/2 as being implicated in induc-
tion and maintenance of iNKT-cell anergy.12-14 We, there-
fore, investigated whether the observed iNKT- and
MAIT-cell dysfunction was related to aberrant PD-1
expression as determined by flow cytometry (Figure 3A).
Interestingly, PD-1 levels were increased both on iNKT
and MAIT cells in BM and PB of NDMM patients (n=14)
as compared to healthy controls (n=14) (Figure 3B).
Comparable results were observed in the 5T33MM
murine model (Online Supplementary Figure S2A). We next
assessed the impact of PD-1 blockade on MAIT cell func-
tion in NDMM patients by performing co-culture experi-
ments in vitro. PBMCs from 7 NDMM patients and 7
healthy controls were incubated for 72 hours in the pres-
ence or not of α-GalCer with or without PD-1 blockade.
Remarkably, activation of MAIT cells by α-GalCer-stimu-
lated iNKT was recovered in NDMM patients in the pres-
ence of PD-1 blockade compared to the condition with 
α-GalCer and PD-1 block alone (Figure 3C). Similar
immune activation by α-GalCer together with PD-1
blockade was found in the 5T33MM model (Online
Supplementary Figure S2B). Successful re-activation of
MAIT cells by PD-1 blockade suggests that the PD-1
pathway is one of the contributors mediating MAIT-cell
dysfunction in MM and disturbing MAIT–iNKT immune
interactions. Moreover, PD-1 blockade combined with α-
GalCer stimulation led to a strong reduction in tumor
load in vivo in the 5T33MM model (Online Supplementary
Figure S3).
To the best of our knowledge, we are the first to
demonstrate that MAIT cells are numerically and func-
tionally impaired in NDMM patients. In addition, this
was found to be linked with iNKT-cell deficiency and ele-
vated PD-1 levels. PD-1 blockade together with α-
GalCer-stimulated iNKT cells rescued this deficiency and
conferred tumor protection in the 5T33MM murine
model. These results open doors for further studies and
stimulate research to elucidate the exact role of MAIT
cells in MM. Apart from evaluating MAIT cells in other
MM patient subsets (monoclonal gammopathy of
unknown significance,  smoldering MM and relapse),
long-term studies in large cohorts of patients will allow
us to evaluate if these alterations can be linked to clinical
outcome. Furthermore, it is of interest to evaluate MAIT-
and iNKT-cell levels in anti-PD-1-treated MM patients.
However, we believe that the impact of MAIT cells in the
MM microenvironment, as well as improvement of their
effector functions via immune checkpoint blockade, rep-
resents a relevant and attractive field for immunosurveil-
lance and immunotherapy in MM. In line with Richter et
al., demonstrating clinical regression after combining
lenalidomide and iNKT-cell stimulation in MM patients,
we provide supplementary evidence for harnessing
invariant T cells to prevent MM.15 Therefore, targeting
invariant T cells which simultaneously stimulate both
innate and adaptive immunity, together with PD-1 block-
ade, might provide a more broad immune activation, and
could, therefore, give more advantageous results com-
pared to current ongoing trials.
Mérédis Favreau,1,2,3 Koen Venken,2,3 Sylvia Faict,1
Ken Maes,1 Kim De Veirman,1 Elke De Bruyne,1 Xavier Leleu,4
Louis Boon,5 Dirk Elewaut,2,3 Karin Vanderkerken1 and Eline
Menu1
MF and KoV are shared first authors; DE, KaV and EM contributed equally
to this work. 
1Department of Hematology and Immunology, Myeloma Center
Brussels, Vrije Universiteit Brussel (VUB), Belgium; 2Department of
Rheumatology, Ghent University Hospital, Belgium; 3Unit for
Molecular Immunology and Inflammation, VIB Inflammation Research
Center, Ghent University, Belgium; 4Service d’Hématologie et Thérapie
Cellulaire, Pôle Régional de Cancérologie, Hopital de la Miléterie,
haematologica 2017; 102:e269
LETTERS TO THE EDITOR
86021 Poitiers, France and  5Bioceros, Utrecht, The Netherlands
Correspondence: Eline.Menu@vub.ac.be 
doi:10.3324/haematol.2017.163758
Acknowledgments: we thank Carine Seynaeve, Sofie Seghers, Tine
Decruy and Nathalie Jouy for their expert technical assistance. 
Funding:  this work was financially supported by Kom op tegen
kanker (KotK) and Fonds voor Wetenschappelijk Onderzoek
Vlaanderen (FWO-Vl). EM. is a post-doctoral fellow supported by the
AXA Research Foundation. KoV, KM, KDV, EDB are post-doctoral
fellows of FWO-Vl. SF is a doctoral fellow supported by FWO-Vl,
MF a doctoral fellow from KotK. DE is supported by FWO-Vl and
the Research Council of Ghent University. DE is also a member of a 
multidisciplinary research platform (MRP) of Ghent University and is
supported by Interuniversity Attraction Pole (IUAP) grant Devrepair
from the Belspo Agency (project P7/07). 
Information on authorship, contributions, and financial & other disclo-
sures was provided by the authors and is available with the online version
of this article at www.haematologica.org.
References
1. Treiner E, Lantz O. CD1d- and MR1-restricted invariant T cells: of
mice and men. Curr Opin Immunol. 2006;18(5):519-526.
2. Debusschere K, Lories RJ, Elewaut D. MAIT cells: not just another
brick in the wall. Ann Rheum Dis. 2016;75(12):5-8.
3. Koay H-F, Gherardin NA, Enders A, et al. A three-stage intrathymic
development pathway for the mucosal-associated invariant T cell lin-
eage. Nat Immunol. 2016;17(11):1300-1311.
4. Wallace ME, Alcantara MB, Minoda Y, et al. An emerging role for
immune regulatory subsets in chronic lymphocytic leukaemia. Int
Immunopharmacol. 2015;28(2):897-900.
5. Won EJ, Ju JK, Cho Y, et al. Clinical relevance of circulating mucosal-
associated invariant T cell levels and their anti-cancer activity in
patients with mucosal-associated cancer. Oncotarget. 2016;
75(46):76274-76290.
6. Favreau M, Vanderkerken K, Elewaut D, et al. Does an NKT-cell-
based immunotherapeutic approach have a future in multiple myelo-
ma? Oncotarget. 2016;7(17):23128-23140.
7. Le Bourhis L, Martin E, Péguillet I, et al. Antimicrobial activity of
mucosal-associated invariant T cells. Nat Immunol. 2010;11(8):701-
708.
8. Miyazaki Y, Miyake S, Chiba A, et al. Mucosal-associated invariant
T cells regulate Th1 response in multiple sclerosis. Int Immunol.
2011;23(9):529-535.
9. Ling L, Lin Y, Zheng W, et al. Circulating and tumor-infiltrating
mucosal associated invariant T (MAIT) cells in colorectal cancer
patients. Sci Rep. 2016;6:20358.
10. Cho Y-N, Kee S-J, Kim T-J, et al. Mucosal-Associated Invariant T Cell
Deficiency in Systemic Lupus Erythematosus. J Immunol.
2014;193(8):3891-3901.
11. Leeansyah E, Ganesh A, Quigley MF, et al. Activation, exhaustion,
and persistent decline of the antimicrobial MR1-restricted MAIT-cell
population in chronic HIV-1 infection. Blood. 2013;121(7):1124-1135.
12. Parekh V V, Wilson MT, Olivares-Villagómez D, et al. Glycolipid
antigen induces long-term natural killer T cell anergy in mice. J Clin
Investig. 2005;115(9):2572-2583.
13. Singh AK, Gaur P, Das SN. Natural killer T cell anergy, co-stimulatory
molecules and immunotherapeutic interventions. Hum Immunol.
2014;75(3):250-260.
14. Iyoda T, Ushida M, Kimura Y, et al. Invariant NKT cell anergy is
induced by a strong TCR-mediated signal plus co-stimulation. Int
Immunol. 2010;22(11):905-913.
15. Richter J, Neparidze N, Zhang L, et al. Clinical regressions and broad
immune activation following combination therapy targeting human
NKT cells in myeloma. Blood. 2013;121(3):423-430.
haematologica 2017; 102:e270
LETTERS TO THE EDITOR
